Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. The lawsuit is sealed in Delaware’s Court of Chancery ...

Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai Inc. has seen a lackluster launch. However, Biogen CEO Chris Viehbacher said on Tuesday that there are a “n ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Shares of the biotech Sage Therapeutics were up nearly 40% on Monday after the company’s partner Biogen threw it a lifeline late Friday. Little has gone right for Sage in recent years ...

Late last week, Biogen made an unsolicited offer to buy one of its partners, brain drug developer Sage Therapeutics. The two biotechnology companies have worked together over the past four years ...

Biogen has offered to purchase Sage’s outstanding shares for $7.22 each, according to a securities filing from Friday. The proposal values Sage at around $442 million. A yearslong partner of ...